Pozanicline (dihydrochloride)

Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a Ki of 16.7 nM for binding to [3H]cytisine sites[1]. Pozanicline is an α4β2-selective nAChR agonist, which binds to rat brain α4β2 nAChR with a Ki of 17 nM while binding to α7 nAChR is insignificant[2].

Product Specifications

CAS Number

[161416-61-1]

Product Name Alternative

ABT-089 (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H302

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pozanicline-dihydrochloride.html

Purity

99.06

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

[H]Cl.[H]Cl.CC(N=CC=C1)=C1OC[C@@H]2CCCN2

Molecular Formula

C11H18Cl2N2O

Molecular Weight

265.18

Precautions

H302

References & Citations

[1]Lin NH, et al. Structure-activity studies on 2-methyl-3- (2 (S) -pyrrolidinylmethoxy) pyridine (ABT-089) : an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem. 1997 Jan 31;40 (3) :385-90.|[2]Marks MJ, et al. Selectivity of ABT-089 for α4β2 and α6β2 nicotinic acetylcholine receptors in brain. Biochem Pharmacol. 2009 Oct 1;78 (7) :795-802.|[3]Yildirim E, et al. ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice. Behav Pharmacol. 2015 Apr;26 (3) :241-8.